Better late than never: Antivirals for dengue

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 7, 2011, Pages 755-757

  Perry, Stuart T ^a   Buck, Michael D ^a   Shresta, Sujan ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

antiviral; dengue; dengue fever; DENV; DHF DSS; vaccine; virus

Indexed keywords

ANTIVIRUS AGENT; CHIMERIVAX; DENGUE VACCINE; UNCLASSIFIED DRUG;

AEDES AEGYPTI; ANTIBODY DEPENDENT ENHANCEMENT; CLINICAL TRIAL (TOPIC); DENGUE; DENGUE VIRUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; ENDEMIC DISEASE; HEALTH CARE FINANCING; HUMAN; MORBIDITY; PATIENT MONITORING; REHYDRATION; REVIEW; VIRUS CLASSIFICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DENGUE; DENGUE VIRUS; DRUG DESIGN; HUMANS; PUBLIC HEALTH; RESEARCH SUPPORT AS TOPIC;

EID: 79961196919     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.68     Document Type: Review

References (18)

1. Special Programme for Research and Training in Tropical Diseases; WHO. Dengue : Guidelines for Diagnosis, Treatment, Prevention, and Control. TDR. WHO, Geneva, Switzerland (2009).
2. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11(3), 480-496 (1998). (Pubitemid 28379096)
3. Rigau-Perez JG. The early use of break-bone fever (Quebranta huesos, 1771) and dengue (1801) in Spanish. Am. J. Trop. Med. Hyg. 59(2), 272-274 (1998). (Pubitemid 28418987)
4. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28(3), 632-649 (2010).
5. Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect. Dis. 9(11), 678-687 (2009).
6. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu. Rev. Immunol. 29, 587-619 (2011).
7. Effler PV, Pang L, Kitsutani P et al. Dengue fever, Hawaii, 2001-2002. Emerg. Infect. Dis. 11(5), 742-749 (2005).
8. Ramos MM, Mohammed H, Zielinski- Gutierrez E et al. Epidemic dengue and dengue hemorrhagic fever at the Texas-Mexico border: results of a household-based seroepidemiologic survey, December 2005. Am. J. Trop. Med. Hyg. 78(3), 364-369 (2008). (Pubitemid 351845181)
9. Franco C, Hynes NA, Bouri N, Henderson DA. The dengue threat to the United States. Biosecur. Bioterror. 8(3), 273-276 (2010).
10. Vastag B. HIV vaccine efforts inch forward. JAMA 286(15), 1826-1828 (2001). (Pubitemid 33010226)
11. De Clercq E. Antiviral drugs in current clinical use. J. Clin. Virol. 30(2), 115-133 (2004). (Pubitemid 38582018)
12. NIAID Biodefense Research Agenda for CDC Category A Agents: Overview of 2006 Progress Report. National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA (2006).
13. Moran M, Guzman J, Henderson K et al. Neglected disease research and development: is the global financial crisis changing R&D? Policy Cures, London, UK (2011).
14. Moran M, Guzman J, Ropars AL et al. Neglected disease research and development: how much are we really spending? PLoS Med. 6(2), e30 (2009).
15. Noble CG, Chen YL, Dong H et al. Strategies for development of Dengue virus inhibitors. Antiviral Res. 85(3), 450-462 (2010).
16. Yauch LE, Shresta S. Mouse models of dengue virus infection and disease. Antiviral Res. 80(2), 87-93 (2008).
17. Labeaud AD, Aksoy S. Neglected funding for vector-borne diseases: a near miss this time, a possible disaster the next time. PLoS Negl. Trop. Dis. 4(10), e847 (2010).
18. Whitehorn J, Farrar J. Dengue. Br. Med. Bull. 95, 161-173 (2010).